AT

Amit Tiwari

Active Director Director DIN 10297791
DIN 10297791 First appointment Aug 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2023
Shareholding value •••• Premium profile

About Amit Tiwari

Data last updated:

Amit Tiwari is a Director at Aripolis Biotech Private Limited (since 2023). The company operates in Pharma. Aripolis Biotech Private Limited reported revenue of ₹5.45 Cr (FY 2025).

DIN 10297791
Primary Designation Director
Industry Pharma
First Appointment 24 Aug 2023
Oldest Company Age 12 yrs
Largest company Aripolis Biotech Private Limited · ₹5.45 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aripolis Biotech Private Limited U24232PB2014PTC038615
Director24 Aug 20232014₹5.45 Cr (FY 2025)Active

Board colleagues of Amit Tiwari

NameDINCompanyDesignation
Vishal08222446Aripolis Biotech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Aripolis Biotech Private Limited
Premium access

Shareholding and investment profile for Amit Tiwari

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Amit Tiwari

Amit Tiwari currently holds 1 directorship: Aripolis Biotech Private Limited (Director, since 24 Aug 2023, revenue ₹5.45 Cr (FY 2025)).

Amit Tiwari was first appointed on 24 Aug 2023 as Director at Aripolis Biotech Private Limited.

The current boards of Amit Tiwari's companies include Vishal (Aripolis Biotech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available